Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 218 posts found.

Lilly building

Eli Lilly predicts revenue growth in 2016

January 5, 2016
Research and Development, Sales and Marketing Eli Lilly, financial reports, marketing, sales

Eli Lilly has set out its financial guidance for 2016, predicting an increase in sales to between $20.2 and $20.7 …

News
FDA sign

FDA approves Lilly/Boehringer Lantus biosimilar

December 17, 2015
Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly

The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …

News
juan_luciano

Juan Luciano appointed to Eli Lilly board

December 16, 2015
Medical Communications Eli Lilly

The board of directors of Eli Lilly has elected Juan Luciano as a new member, effective February 1 2016. Luciano …

Appointment
zometa

Cancer drugs prices vary up to 388% between high-income countries

December 4, 2015
Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology

The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …

News
keytruda

Lilly and Merck extend immuno-oncology collaboration

November 20, 2015
Medical Communications, Research and Development Eli Lilly, Merck

Eli Lilly and Merck have announced the extension of their existing collaboration to evaluate the safety and efficacy of the …

News

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …

News
Jardiance

More positive CV data for Boehringer and Lilly’s Jardiance

September 21, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes

Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …

News
boehringer_lilly

New Boehringer and Lilly type 2 diabetes treatment gets FDA nod

August 28, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, Synjardy, type 2 diabetes

The FDA has approved Synjardy, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. …

News
alimta

Lilly defeats Teva in US court over Alimta patent

August 26, 2015
Research and Development, Sales and Marketing Alimta, Eli Lilly, Teva Pharmaceutical, lung cancer

Eli Lilly has won a case in a US federal court, in a battle over Teva’s attempt to create a …

News
Abasaglar

Lilly and Boehringer launch biosimilar insulin in the UK

August 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly

Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …

News
lilly_corporate_hq

Lilly and Boehringer’s Jardiance diabetes drug reduces cardiovascular risks

August 21, 2015
Medical Communications, Research and Development Boehringer Ingelheim, Eli Lilly, diabetes drugs

Eli Lilly’s diabetes drug Jardiance (empagliflozin) has shown in a study to be the very first blood sugar lowering drug …

News
alzheimers_brain

Lilly, Biogen and Roche debut Alzheimer’s disease drug results

July 22, 2015
Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly

Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …

News
lilly_logo_building

Lilly and AstraZeneca collaborate on cancer trials

May 29, 2015
Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I

AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …

News

UK pharma commits at least ‘one code breach a week’

February 18, 2015
Medical Communications, Sales and Marketing ABPI, AstraZeneca, Bayer, Eli Lilly, GSK, Novartis, Novo Nordisk, PMCPA, Pfizer, code

Pharma companies commit unethical marketing practices on average more than once a week in the UK academic analysis has found. …

News
Cyramza

Lilly to market stomach cancer drug in Europe

December 22, 2014
Sales and Marketing Eli Lilly, Europe, FDA, US, cyramza, ramucirumab, stomach cancer

Eli Lilly has been granted permission by the European Commission to market Cyramza in Europe. Lilly’s Cyramza (ramucirumab) is the …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025